Literature DB >> 21717471

Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma.

Songsak Kiatchoosakun1, Chaiyasith Wongvipaporn, Ratanavadee Nanagara, Brian D Hoit.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is a well-known complication of systemic sclerosis (SSc). Doppler echocardiographic screening for the detection of PAH (by measuring right ventricular systolic pressure [RVSP]) is therefore recommended for all patients with SSc. However, the validity of RVSP as a predictor of mortality in patients with SSc is not well established. HYPOTHESIS: Doppler-determined PAH identifies a high-risk subset of patients with SSc with decreased survival.
METHODS: We performed echocardiography in 155 consecutive patients with SSc between May 2005 and July 2006 and tested the value of an RVSP level of ≥36 mm Hg to predict mortality. Cox proportional hazards model was used to examine the individual relationship between each variable and the mortality rate.
RESULTS: Tricuspid regurgitant jets for RVSP determination were quantified in 129 patients (82.6%), of which 47 (36.4%) had RVSP ≥36 mm Hg. The median follow-up time was 34 months. The 1-, 2-, and 3-year survival rates were significantly lower among SSc patients with RVSP ≥36 vs ≤36 mm Hg (82%, 78%, and 67% vs 98%, 90%, and 86%, respectively, P < 0.01 by Wilcoxon test). In a multivariate analysis including echocardiographic and clinical variables, only an RVSP ≥36 mm Hg and a New York Heart Association III/IV class were associated with increased mortality; the respective Cox hazard ratios were 2.22 (95% confidence interval [CI]: 1.01-4.89, P = 0.048) and 4.77 (95% CI: 2.09-10.90, P = 0.000).
CONCLUSIONS: Our results indicate that Doppler RVSP identifies a high-risk subset and supports the use of Doppler RVSP as a screening test in patients with SSc who may warrant early treatment of their PAH.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21717471      PMCID: PMC6652343          DOI: 10.1002/clc.20920

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

1.  Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension.

Authors:  Xiao-Wei Song; Lu-Lu Zou; Ling Cui; Song-Hua Li; Yong-Wen Qin; Xian-Xian Zhao; Qing Jing
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

2.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

3.  Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension.

Authors:  Mingting Liang; Ying Pang; Shuguang Zhang; Mei Zhang
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

4.  Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients.

Authors:  Ami A Shah; Shang-En Chung; Fredrick M Wigley; Robert A Wise; Laura K Hummers
Journal:  Ann Rheum Dis       Date:  2012-08-11       Impact factor: 19.103

5.  Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population.

Authors:  Eric Hachulla; Pierre Clerson; Paolo Airò; Giovanna Cuomo; Yannick Allanore; Paola Caramaschi; Edoardo Rosato; Patricia E Carreira; Valeria Riccieri; Marta Sarraco; Christopher P Denton; Gabriela Riemekasten; Maria Rosa Pozzi; Silvana Zeni; Carmen Marina Mihai; Susanne Ullman; Oliver Distler; Simona Rednic; Vanessa Smith; Ulrich A Walker; Marco Matucci-Cerinic; Ulf Müller-Ladner; David Launay
Journal:  Rheumatology (Oxford)       Date:  2015-01-17       Impact factor: 7.580

6.  Prognostic relevance of elevated pulmonary arterial pressure assessed non-invasively: Analysis in a large patient cohort with invasive measurements in near temporal proximity.

Authors:  Sebastian Greiner; Andreas Jud; Matthias Aurich; Christoph Geisenberger; Lorenz Uhlmann; Thomas Hilbel; Meinhard Kieser; Hugo A Katus; Derliz Mereles
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

7.  Right ventricular systolic pressure - Non-invasive bedside predictor of mortality and readmission in heart failure with reduced and preserved ejection fraction hospitalization.

Authors:  Monil Majmundar; Tikal Kansara; Ashish Kumar; Hansang Park; Palak Shah; Rajkumar Doshi; Harshvardhan Zala; Hossam Amin; Shobhana Chaudhari; Ankur Kalra
Journal:  Indian Heart J       Date:  2022-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.